© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Converge Coverage
PIONEER-HF Extension: Don’t stall starting sacubitril/valsartan
REPORTING FROM ACC 19
Related Articles
Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients with Cirrhosis and AF
April 14, 2019
Clinical question: What is the effectiveness and safety of apixaban, rivaroxaban, and warfarin in patients with cirrhosis and atrial fibrillation? Background: The use of direct oral anticoagulants...
Finerenone Reduces HF Events in Patients with Preserved Ejection Fraction
April 14, 2019
Clinical question: Does finerenone improve outcomes in patients with heart failure (HF) with mildly reduced or preserved ejection fraction? Background: Steroidal mineralocorticoid receptor...
Empagliflozin After Acute Myocardial Infarction
April 14, 2019
Clinical question: Does empagliflozin improve cardiovascular outcomes in patients who have had an acute myocardial infarction? Background: Studies have shown that empagliflozin improves...
Safety of Diltiazem in Patients Taking Apixaban or Rivaroxaban
April 14, 2019
Clinical question: Does diltiazem increase the risk of major bleeding in patients on apixaban or rivaroxaban? Background: Diltiazem is a potent CYP3A4 inhibitor and a mild P-glycoprotein inhibitor....